A review of the Ankylosing Spondylitis
(Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Secondary endpoints assessed signs and symptoms, physical function and quality of life measures at Week 16 including: ASAS40 response, change from baseline in high-sensitivity C-reactive protein (hsCRP), ASAS5/6 improvement; changes from baseline in total BASDAI score, Medical Outcomes Study Short Form-36 Health Survey physical component summary score (SF-36 PCS), Ankylosing Spondylitis
Quality of Life score (ASQoL), ASAS partial remission, and overall safety and tolerability.
In AS patients, there was no significant correlation between PainDETECT and Bath Ankylosing Spondylitis
Disease Activity Index, and Bath Ankylosing Spondylitis
Functional Index (p=0.
is a chronic inflammatory form of arthritis that affects the spinal joints.
Distribution of HLA-B27 subtypes in ankylosing spondylitis
in an Israeli population.
Clinical disease variables included duration of morning stiffness (in minutes), degree of spinal pain at night (as represented on a 100-mm visual-analogue scale, with 0 mm indicating the absence of pain and 100 mm the most severe pain), Ankylosing Spondylitis
Disease Activity Index, (16) Bath Ankylosing Spondylitis
Disease Functional Index (BASFI), (17) physician's and patient's global assessment of disease activity, Schober test (cm), chest expansion (cm), and mean occiput-to-wall measurement (cm).
Recognition regulatory process that agreed to ankylosing spondylitis
as a new
This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis
(Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
This was the unexpected finding of a comprehensive analysis of trends in medication use over a 12-year period among 1,018 ankylosing spondylitis
patients participating in the ongoing multicenter Prospective Study of Outcomes in Ankylosing Spondylitis
Clinical and functional activities were evaluated according to Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI), (22) Bath Ankylosing Spondylitis
Functional Index (BASFI) (23) scores.
was similar to the RMP in rheumatoid arthritis (RA) and ankylosing spondylitis
(AS) patients who were switched from the RMP to the biosimilar infliximab, with no additional safety signals.
8 mL (adalimumab; [genetical recombination], "HUMIRA"), a fully human anti-TNF-alpha monoclonal antibody formulation, has been lifted for use in patients with ankylosing spondylitis